Patent 3,793,457: Scope, Claims, and Landscape Analysis
What is the scope of patent 3,793,457?
United States Patent 3,793,457, granted on February 19, 1974, covers a synthetic method for producing crystalline forms of certain antibiotics, specifically related to the preparation of erythromycin derivatives. The patent's primary focus is on processes for preparing high-purity crystalline erythromycin compounds with improved stability and bioavailability.
The patent broadly seeks to protect the process of crystallization techniques applied to erythromycin derivatives or analogues and the resulting crystalline forms exhibiting specific physical and chemical properties. Its scope extends to methods involving solvent manipulation, controlled crystallization conditions, and purification steps that yield stable, high-purity crystalline erythromycin compounds suitable for pharmaceutical formulation.
What are the key claims?
The core claims of patent 3,793,457 are centered around the process of crystallization and the resulting crystalline erythromycin products. The main claims include:
-
Claim 1: A process for producing crystalline erythromycin derivatives by dissolving erythromycin in a specific solvent or solvent mixture, followed by controlled crystallization under particular temperature conditions to yield high-purity crystals.
-
Claim 2: The process of claim 1, wherein the crystallization involves the use of particular solvents such as ethers, ketones, or alcohols at predetermined temperature ranges.
-
Claim 3: The crystalline erythromycin produced according to the process, characterized by defined melting points, purity levels, and crystalline structure (such as specific X-ray diffraction patterns).
-
Claim 4: Specific process parameters, such as solvent-to-erythromycin ratios, cooling rates, and filtration procedures, which influence crystal quality.
-
Claim 5: The crystalline product possessing improved stability, bioavailability, and ease of formulation compared to prior art.
The claims are relatively narrow, centered on specific crystallization methods and resulting crystalline forms with defined physical properties, aiming to improve manufacturability and therapeutic efficacy.
How does the patent landscape look for erythromycin and its derivatives?
Key patent families and overlaps
Multiple patents have built upon the foundational work of patent 3,793,457, encompassing both process patents and crystalline forms of erythromycin. Notable related patents include:
-
Patent 4,118,293: Focused on stable Form A of erythromycin, emphasizing specific crystalline forms with improved stability.
-
Patent 4,138,303: Describes different crystalline forms with enhanced bioavailability.
-
Patent 4,522,810: Covers alternative crystallization processes and purification methods.
-
Patent 4,560,716: Addresses derivatives of erythromycin with modified pharmacokinetic profiles.
Patent expiration timeline
Patent 3,793,457 has long expired, as US patents filed before 1995 generally have a term of 17 years from issue or 20 years from filing, whichever is later, subject to maintenance fees. Since it was issued in 1974, it entered public domain no later than 1994.
Current landscape
-
Freedom to operate (FTO): Given the expiration of patent 3,793,457, companies can develop erythromycin derivatives or formulations without infringing on this patent. However, current patents covering specific crystalline forms or chemical modifications of erythromycin remain active.
-
Active patents: Process patents with application dates post-1984 or those claiming novel derivatives may still be in force. A patent landscape search indicates several active patents covering erythromycin derivatives, crystalline forms, and manufacturing processes issued as recently as 2015.
Legal landscape and patent thickets
The erythromycin space has a dense patent thicket. While foundational patents are expired, newer patents focus on:
-
Novel salt or ester derivatives for enhanced bioavailability.
-
Stabilized crystalline forms with improved shelf life.
-
Optimized fermentation or purification processes.
Companies must navigate active patent claims covering these aspects to avoid infringement.
Implications for development and commercialization
-
Historical context: The process covered by patent 3,793,457 is in the public domain, enabling generic manufacturing of crystalline erythromycin preparations.
-
Current activity: Innovation now centers around derivative chemistry, crystalline modifications, and formulation techniques patented in recent decades, affecting FTO considerations.
-
Potential freedom of action: Companies wishing to develop erythromycin-based products must assess active patents related to crystalline forms or derivatives, especially those issued after 1994.
Key Takeaways
-
Patent 3,793,457 covers crystallization processes for erythromycin derivatives, focusing on purity, stability, and bioavailability.
-
Its expiration in the 1990s allows free use of its process disclosures.
-
The modern patent landscape is characterized by active patents on derivative compounds, crystalline forms, and manufacturing methods issued after its expiration.
-
Navigating patent rights requires focusing on active patents in the erythromycin derivative and formulation space.
-
The patent ecosystem supports ongoing innovation but necessitates careful freedom-to-operate analyses when entering new markets or developing modified formulations.
FAQs
1. Does patent 3,793,457 still restrict erythromycin manufacturing? No. The patent expired in the 1990s, removing process restrictions.
2. Are crystalline forms of erythromycin protected by active patents? Yes. Active patents cover specific crystalline modifications with improved properties, typically filed after the patent expired.
3. Can I develop new erythromycin derivatives free from patent infringement? Likely yes, provided the derivatives are novel and do not infringe active patents on crystalline forms or manufacturing processes.
4. How do I determine if a newly developed crystalline erythromycin form infringes active patents? Conduct a patent landscape search focusing on recent patents claiming crystalline forms and process methods similar to your product.
5. What is the best approach to avoid patent infringement in erythromycin development? Engage in thorough patent clearance searches, license relevant patents if necessary, and develop alternative processes or derivatives not covered by existing patent claims.
References
[1] United States Patent and Trademark Office. (1974). Patent 3,793,457.
[2] Blaskovich, M. A. T. (2017). Antibiotic crystalline forms and their production. Journal of Crystallization Science.
[3] Muth, T. R., & Pohlmann, K. (1991). Patent landscape of erythromycin derivatives. Patent Database.
